About Eli Lilly and (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Industry, Sector and Symbol
Trailing P/E Ratio40.7095238095238
Forward P/E Ratio20.26
Sales & Book Value
Annual Sales$21.22 billion
Price / Sales4.44
Cash Flow$4.72 per share
Price / Cash18.11
Book Value$12.76 per share
Price / Book6.70
Net Income$2.74 billion
Return on Equity30.27%
Return on Assets10.82%
Eli Lilly and (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly and's stock symbol?
Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?
Eli Lilly and announced a quarterly dividend on Monday, December 11th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share on Friday, March 9th. This represents a $2.25 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and's previous quarterly dividend of $0.52. View Eli Lilly and's Dividend History.
How were Eli Lilly and's earnings last quarter?
Eli Lilly and Co (NYSE:LLY) announced its quarterly earnings results on Tuesday, October, 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and's revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.88 EPS. View Eli Lilly and's Earnings History.
When will Eli Lilly and make its next earnings announcement?
What guidance has Eli Lilly and issued on next quarter's earnings?
Eli Lilly and issued an update on its FY18 earnings guidance on Wednesday, December, 13th. The company provided earnings per share guidance of $4.60-4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.65. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $23.07 billion.Eli Lilly and also updated its FY17 guidance to $4.15-4.25 EPS.
Where is Eli Lilly and's stock going? Where will Eli Lilly and's stock price be in 2018?
15 brokerages have issued 12 month price objectives for Eli Lilly and's stock. Their forecasts range from $73.00 to $115.00. On average, they expect Eli Lilly and's share price to reach $94.60 in the next year. View Analyst Ratings for Eli Lilly and.
What are Wall Street analysts saying about Eli Lilly and stock?
Here are some recent quotes from research analysts about Eli Lilly and stock:
- 1. According to Zacks Investment Research, "Lilly’s third-quarter 2017 results were strong with the company beating estimates on both counts. Lilly also raised its sales and earnings outlook for the second time this year mainly backed by strong uptake trends of new products. Lilly is also exploring strategic alternatives for the Animal Health business, a prudent decision in our view. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. However, key drug Alimta will continue to be impacted by competition. Meanwhile, the recent high-profile pipeline setbacks, competition from immuno-oncology agents, loss of exclusivity for many drugs, and weak performance of the Animal Health segment this year are an investor concern." (10/30/2017)
- 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
- 3. UBS Group AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)
Who are some of Eli Lilly and's key competitors?
Some companies that are related to Eli Lilly and include Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Celgene (CELG), GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG), Beximco Pharmaceuticals (BXP), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Dr.Reddy's Laboratories (RDY) and Catalent (CTLT).
Who are Eli Lilly and's key executives?
Eli Lilly and's management team includes the folowing people:
- David A. Ricks, Chairman of the Board, President, Chief Executive Officer (Age 49)
- Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories (Age 63)
- Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer (Age 48)
- Michael J. Harrington, Senior Vice President, General Counsel (Age 54)
- Stephen F. Fry, Senior Vice President - Human Resources and Diversity (Age 51)
- Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA (Age 50)
- Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
- Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications (Age 58)
- Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications
- Jeffrey N. Simmons, Senior Vice President and President - Elanco Animal Health (Age 49)
Who owns Eli Lilly and stock?
Eli Lilly and's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.18%), Bank of Montreal Can (0.42%), Schwab Charles Investment Management Inc. (0.39%), Hexavest Inc. (0.12%), National Pension Service (0.07%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.
Who sold Eli Lilly and stock? Who is selling Eli Lilly and stock?
Eli Lilly and's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., DnB Asset Management AS, Atria Investments LLC, Exxonmobil Investment Management Inc. TX, World Asset Management Inc, First Citizens Bank & Trust Co., NEXT Financial Group Inc and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and.
Who bought Eli Lilly and stock? Who is buying Eli Lilly and stock?
Eli Lilly and's stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Pensionfund DSM Netherlands, Oakbrook Investments LLC, Nisa Investment Advisors LLC, National Pension Service and Pensionfund Sabic. Company insiders that have bought Eli Lilly and stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and.
How do I buy Eli Lilly and stock?
Shares of Eli Lilly and can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly and's stock price today?
One share of Eli Lilly and stock can currently be purchased for approximately $85.49.
How big of a company is Eli Lilly and?
Eli Lilly and has a market capitalization of $94.13 billion and generates $21.22 billion in revenue each year. The company earns $2.74 billion in net income (profit) each year or $2.10 on an earnings per share basis. Eli Lilly and employs 41,975 workers across the globe.
How can I contact Eli Lilly and?
Eli Lilly and's mailing address is Lilly Corporate Ctr, Drop Code 1112, INDIANAPOLIS, IN 46285, United States. The company can be reached via phone at +1-317-2762000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly and (LLY)MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eli Lilly and (NYSE:LLY) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.53||2.53||2.50||2.63|
|Ratings Breakdown: ||1 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$94.60||$91.60||$90.18||$88.67|
|Price Target Upside: ||8.76% upside||5.64% upside||3.38% upside||6.01% upside|
Eli Lilly and (NYSE:LLY) Consensus Price Target History
Eli Lilly and (NYSE:LLY) Analyst Ratings History
(Data available from 1/21/2016 forward)
Eli Lilly and (NYSE:LLY) Earnings History and Estimates Chart
Eli Lilly and (NYSE LLY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/24/2017||Q3 2017||$1.03||$1.05||$5.52 billion||$5.66 billion||View||N/A|
|7/25/2017||Q2 2017||$1.05||$1.11||$5.60 billion||$5.82 billion||View||N/A|
|4/25/2017||Q1 17||$0.96||$0.98||$5.22 billion||$5.23 billion||View||N/A|
|1/31/2017||Q416||$0.98||$0.95||$5.54 billion||$5.76 billion||View||N/A|
|10/25/2016||Q316||$0.96||$0.88||$4.23 billion||$5.19 billion||View||Listen|
|7/26/2016||Q216||$0.86||$0.86||$5.14 billion||$5.40 billion||View||Listen|
|4/26/2016||Q116||$0.85||$0.83||$4.82 billion||$4.87 billion||View||Listen|
|1/28/2016||Q415||$0.78||$0.78||$5.33 billion||$5.38 billion||View||Listen|
|10/22/2015||Q315||$0.76||$0.89||$4.99 billion||$4.96 billion||View||Listen|
|7/23/2015||Q215||$0.74||$0.90||$4.89 billion||$4.98 billion||View||Listen|
|4/23/2015||Q115||$0.76||$0.87||$4.62 billion||$4.64 billion||View||N/A|
|1/30/2015||Q414||$0.74||$0.75||$5.21 billion||$5.12 billion||View||N/A|
|10/23/2014||Q314||$0.66||$0.66||$4.83 billion||$4.88 billion||View||Listen|
|7/24/2014||Q214||$0.66||$0.68||$4.88 billion||$4.94 billion||View||N/A|
|4/24/2014||Q114||$0.70||$0.70||$4.78 billion||$4.68 billion||View||N/A|
|1/30/2014||Q413||$0.72||$0.74||$5.46 billion||$5.81 billion||View||Listen|
|10/23/2013||Q313||$1.04||$1.11||$5.76 billion||$5.77 billion||View||N/A|
|7/24/2013||Q2 2013||$1.01||$1.16||$5.82 billion||$5.93 billion||View||N/A|
|4/24/2013||Q1 2013||$1.05||$1.14||$5.66 billion||$5.60 billion||View||N/A|
|1/29/2013||Q4 2012||$0.82||$0.85||$5.78 billion||$5.96 billion||View||N/A|
Eli Lilly and (NYSE:LLY) Earnings Estimates
2018 EPS Consensus Estimate: $4.67
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Eli Lilly and (NYSE:LLY) Dividend Information
|Dividend Growth:||2.00% (3 Year Average)|
|Payout Ratio:||99.05% (Trailing 12 Months of Earnings) |
49.29% (Based on This Year's Estimates)
44.73% (Based on Next Year's Estimates)
|Track Record:||3 Years of Consecutive Dividend Growth|
Eli Lilly and (NYSE:LLY) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 76.35%
Eli Lilly and (NYSE LLY) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/13/2017||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$88.20||$17,640,000.00||123,084,104|| |
|12/11/2017||Jeffrey N Simmons||SVP||Sell||12,500||$86.46||$1,080,750.00||124,522|| |
|12/4/2017||Susan Mahony||SVP||Sell||36,585||$86.18||$3,152,895.30||54,885|| |
|11/10/2017||Alfonso G Zulueta||SVP||Sell||2,003||$83.67||$167,591.01||43,580|| |
|10/4/2017||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$86.81||$17,796,050.00|| |
|9/29/2017||Lilly Endowment Inc||Major Shareholder||Sell||195,000||$85.14||$16,602,300.00||123,513,247|| |
|9/15/2017||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$82.53||$15,680,700.00||123,682,287|| |
|8/31/2017||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$81.06||$14,590,800.00||123,865,804|| |
|7/31/2017||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$83.09||$18,279,800.00||124,049,283|| |
|6/22/2017||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$84.43||$17,730,300.00||124,265,804|| |
|6/20/2017||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$83.05||$17,855,750.00||124,475,804|| |
|6/12/2017||Melissa S Barnes||Insider||Sell||1,900||$80.78||$153,482.00||14,041|| |
|6/9/2017||Michael J Harrington||VP||Sell||22,833||$79.97||$1,825,955.01||62,056|| |
|5/4/2017||Enrique A Conterno||SVP||Sell||25,000||$82.76||$2,069,000.00||114,217|| |
|3/30/2017||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$84.67||$17,780,700.00||124,690,804|| |
|2/17/2017||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$80.27||$18,462,100.00||125,125,804|| |
|2/6/2017||Alfonso G Zulueta||SVP||Sell||15,000||$77.66||$1,164,900.00||45,583|| |
|2/3/2017||Derica W Rice||EVP||Sell||11,162||$77.14||$861,036.68||58,443|| |
|2/2/2017||Donald A Zakrowski||Insider||Sell||2,000||$77.52||$155,040.00||886|| |
|2/1/2017||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.35||$17,017,000.00||125,359,047|| |
|12/16/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.59||$14,518,000.00||125,649,408|| |
|12/16/2016||Melissa S Barnes||Insider||Sell||2,093||$82.23||$172,107.39||8,169|| |
|12/16/2016||R David Hoover||Director||Buy||500||$71.85||$35,925.00||33,504|| |
|12/16/2016||Susan Mahony||SVP||Sell||20,242||$72.65||$1,470,581.30||67,802|| |
|10/5/2016||Maria A Crowe||Insider||Sell||2,248||$81.37||$182,919.76||94,319|| |
|8/15/2016||Jackson P Tai||Director||Buy||5,773||$80.43||$464,322.39||42,306|| |
|8/12/2016||Jackson P Tai||Director||Buy||2,560||$80.42||$205,875.20||42,110|| |
|7/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$82.94||$17,002,700.00||125,775,804|| |
|7/28/2016||Donald A Zakrowski||Insider||Sell||1,213||$83.16||$100,873.08||1,300|| |
|7/28/2016||Lilly Endowment Inc||Major Shareholder||Sell||240,000||$82.87||$19,888,800.00||126,020,570|| |
|7/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$79.54||$16,703,400.00||126,220,804|| |
|7/7/2016||Lilly Endowment Inc||Major Shareholder||Sell||225,000||$79.14||$17,806,500.00||126,442,509|| |
|6/30/2016||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$78.46||$16,868,900.00||126,808,704|| |
|6/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.86||$17,129,200.00||126,963,785|| |
|6/10/2016||Melissa S Barnes||SVP||Sell||992||$73.77||$73,179.84||10,710|| |
|5/31/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$75.12||$15,024,000.00||127,090,804|| |
|5/12/2016||Jackson P Tai||Director||Buy||1,080||$75.75||$81,810.00||40,600|| |
|5/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$75.86||$14,413,400.00||127,295,910|| |
|5/2/2016||Donald A Zakrowski||CAO||Sell||1,600||$75.86||$121,376.00||3,113|| |
|4/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$75.44||$13,579,200.00||127,481,005|| |
|4/27/2016||Alfonso G Zulueta||SVP||Sell||12,000||$76.27||$915,240.00||45,101|| |
|4/8/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$74.29||$14,858,000.00||127,660,804|| |
|2/5/2016||Stephen F Fry||SVP||Sell||15,230||$78.87||$1,201,190.10||59,690|| |
|2/3/2016||David A. Ricks||SVP||Sell||5,733||$77.66||$445,224.78||79,403|| |
|2/3/2016||Derica W. Rice||CFO||Sell||10,483||$77.78||$815,367.74||36,931|| |
|2/1/2016||Jackson P Tai||Director||Buy||3,170||$78.62||$249,225.40||39,487|| |
|1/29/2016||Alfonso G Zulueta||SVP||Sell||5,000||$78.75||$393,750.00||57,101|| |
|12/21/2015||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$86.00||$17,630,000.00||127,860,804|| |
|12/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$85.60||$18,404,000.00||128,065,804|| |
|12/9/2015||Enrique A Conterno||VP||Sell||25,000||$83.88||$2,097,000.00||88,131|| |
|12/2/2015||Lilly Endowment Inc||major shareholder||Sell||210,000||$85.09||$17,868,900.00||128,280,804|| |
|11/20/2015||Lilly Endowment Inc||major shareholder||Sell||205,000||$84.54||$17,330,700.00||128,490,804|| |
|10/29/2015||Lilly Endowment Inc||major shareholder||Sell||200,000||$82.28||$16,456,000.00||128,695,804|| |
|10/9/2015||Lilly Endowment Inc||major shareholder||Sell||215,000||$85.86||$18,459,900.00||128,895,804|| |
|10/5/2015||Lilly Endowment Inc||major shareholder||Sell||260,000||$86.46||$22,479,600.00||129,110,804|| |
|9/18/2015||Lilly Endowment Inc||major shareholder||Sell||250,000||$89.04||$22,260,000.00||129,370,804|| |
|6/10/2015||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$82.39||$17,301,900.00|| |
|6/4/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$77.90||$15,580,000.00|| |
|5/29/2015||Jeffrey N Simmons||SVP||Sell||20,000||$78.08||$1,561,600.00|| |
|5/20/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$73.43||$13,951,700.00|| |
|5/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.83||$14,566,000.00|| |
|5/8/2015||Lilly Endowment Inc||Major Shareholder||Sell||195,000||$73.28||$14,289,600.00|| |
|5/1/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$73.09||$14,618,000.00|| |
|3/30/2015||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$73.94||$13,309,200.00|| |
|3/23/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$76.97||$14,624,300.00|| |
|3/9/2015||Stephen F Fry||SVP||Sell||4,000||$69.27||$277,080.00|| |
|2/4/2015||David A Ricks||SVP||Sell||3,147||$69.99||$220,258.53|| |
|2/4/2015||Derica W Rice||CFO||Sell||5,316||$70.00||$372,120.00|| |
|2/4/2015||Jan M Lundberg||EVP||Sell||11,085||$70.08||$776,836.80|| |
|2/3/2015||Jan M Lundberg||EVP||Sell||121,711||$70.78||$8,614,704.58|| |
|2/2/2015||David A Ricks||SVP||Sell||4,769||$71.51||$341,031.19|| |
|2/2/2015||Derica W Rice||CFO||Sell||10,068||$71.84||$723,285.12|| |
|12/4/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$71.92||$13,664,800.00|| |
|12/2/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$70.14||$12,625,200.00|| |
|11/13/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$67.73||$13,546,000.00|| |
|11/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$67.00||$12,060,000.00|| |
|11/4/2014||Fionnuala M Walsh||SVP||Sell||15,000||$67.00||$1,005,000.00|| |
|11/3/2014||Enrique A Conterno||VP||Sell||5,000||$66.03||$330,150.00|| |
|10/31/2014||Fionnuala M Walsh||SVP||Sell||7,376||$66.58||$491,094.08|| |
|10/31/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$66.40||$12,616,000.00|| |
|10/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||175,000||$66.58||$11,651,500.00|| |
|10/24/2014||Maria A Crowe||Insider||Sell||2,750||$65.77||$180,867.50|| |
|10/6/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$65.63||$13,782,300.00|| |
|10/1/2014||Enrique A Conterno||VP||Sell||5,000||$64.86||$324,300.00|| |
|9/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$65.07||$13,014,000.00|| |
|9/10/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$64.77||$13,601,700.00|| |
|9/3/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$63.99||$12,798,000.00|| |
|9/2/2014||Enrique A Conterno||VP||Sell||5,000||$63.60||$318,000.00|| |
|7/29/2014||Lilly Endowment Inc||Major Shareholder||Sell||250,000||$63.03||$15,757,500.00|| |
|7/28/2014||Susan Mahony||SVP||Sell||2,065||$63.30||$130,714.50|| |
|7/25/2014||Enrique A Conterno||VP||Sell||10,000||$63.79||$637,900.00|| |
|7/25/2014||Susan Mahony||SVP||Sell||30,000||$63.90||$1,917,000.00|| |
|7/1/2014||Lilly Endowment Inc||Major Shareholder||Sell||235,000||$62.30||$14,640,500.00|| |
|6/25/2014||Lilly Endowment Inc||Major Shareholder||Sell||245,000||$62.68||$15,356,600.00|| |
|6/20/2014||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$61.55||$14,156,500.00|| |
|6/16/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$58.73||$11,746,000.00|| |
|6/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$59.53||$11,310,700.00|| |
|5/21/2014||Lilly Endowment Inc||major shareholder||Sell||230,000||$58.90||$13,547,000.00||134,690,804|| |
|5/12/2014||Jackson Tai||Director||Buy||17,157||$59.19||$1,015,522.83||32,180|| |
|5/12/2014||Lilly Endowment Inc||major shareholder||Sell||210,000||$59.33||$12,459,300.00||134,920,804|| |
|5/6/2014||Lilly Endowment Inc||major shareholder||Sell||190,000||$58.79||$11,170,100.00||135,130,804|| |
|4/29/2014||Lilly Endowment Inc||major shareholder||Sell||200,000||$59.43||$11,886,000.00||135,320,804|| |
|4/28/2014||Lilly Endowment Inc||major shareholder||Sell||150,000||$58.64||$8,796,000.00||135,520,804|| |
|8/15/2013||Enrique Conterno||VP||Sell||5,000||$53.79||$268,950.00||57,177|| |
|7/29/2013||Jacques Tapiero||SVP||Sell||7,500||$53.74||$403,050.00|| |
|7/15/2013||Enrique A Conterno||VP||Sell||5,000||$51.43||$257,150.00|| |
|6/17/2013||Enrique A Conterno||VP||Sell||5,000||$52.45||$262,250.00|| |
|5/15/2013||Enrique A Conterno||VP||Sell||5,000||$56.15||$280,750.00|| |
|5/10/2013||Jeffrey N Simmons||SVP||Sell||10,000||$54.49||$544,900.00|| |
|3/26/2013||Susan Mahony||SVP||Sell||5,000||$56.00||$280,000.00|| |
Eli Lilly and (NYSE LLY) News Headlines
Eli Lilly and (NYSE:LLY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement
Eli Lilly and (NYSE LLY) Stock Chart for Sunday, January, 21, 2018